- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
HHS' Balancing Act to Keep Healthcare Costs Down
The proposed federal guidelines are currently open for feedback are calling for greater transparency with informed consent and CER, which might stifle innovation, according to some advocacy groups.
A patient plagued with difficult-to-control asthma is at the end of his rope until his doctor suggests joining a clinical trial. He's no longer just a patient but also a research subject, and he'll be testing one existing treatment approach while others stay on a different therapy. These kinds of studies are the bedrock of medical science—they ensure that medicines and procedures are safe and effective. Before agreeing, he needs to know what he's getting himself into—the potential benefits and harms, known as "informed consent."
The federal government has regulated informed consent for decades. But some advocacy organizations are warning that proposed federal guidelines—which could be finalized in the upcoming year—could have a chilling effect on innovation, while fundamentally altering which studies get done.
Link to the complete article on MedpageToday: http://bit.ly/15kCC6J
Review Emphasizes Potential Infection Risks With BTK Inhibitors
November 2nd 2024Although Bruton tyrosine kinase (BTK) inhibitor monotherapy in chronic lymphocytic leukemia (CLL) has been a game-changer, patients have significantly increased risks of infection, especially in the upper respiratory tract.
Read More
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
PAH Treatment Outcomes Similar Regardless of Diagnosis Time
November 1st 2024The study findings underscore the importance of early initiation of macitentan and tadalafil among patients who have pulmonary arterial hypertension (PAH), and represent a shift in understanding of prognosis based on diagnosis timing.
Read More
